Cidara Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CDTX Nasdaq 8731 http://www.cidara.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cidara Therapeutics Inc

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis - Jan 25th, 2023 4:02 pm
Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform - Jan 4th, 2023 1:00 pm
Cidara Therapeutics (NASDAQ:CDTX) shareholders are up 19% this past week, but still in the red over the last five years - Jan 4th, 2023 11:09 am
Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388 - Dec 1st, 2022 1:00 pm
Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split - Nov 29th, 2022 1:00 pm
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet - Nov 28th, 2022 1:00 pm
Cidara Therapeutics to Participate in the World Antiviral Congress 2022 - Nov 23rd, 2022 1:00 pm
Cidara Therapeutics Third Quarter 2022 Earnings: Beats Expectations - Nov 9th, 2022 10:41 am
Cidara Therapeutics to Present at the Stifel Healthcare Conference - Nov 8th, 2022 1:00 pm
Is Cidara Therapeutics (NASDAQ:CDTX) In A Good Position To Deliver On Growth Plans? - Nov 7th, 2022 4:58 pm
Cidara Therapeutics (CDTX) Q3 Earnings Miss Estimates - Nov 3rd, 2022 11:05 pm
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Nov 3rd, 2022 9:47 pm
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022 - Oct 17th, 2022 12:00 pm
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma - Oct 4th, 2022 12:00 pm
Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review - Sep 21st, 2022 2:27 pm
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis - Sep 20th, 2022 8:05 pm
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza - Sep 13th, 2022 12:00 pm
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference - Sep 6th, 2022 12:00 pm
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates - Aug 9th, 2022 11:25 pm
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Aug 9th, 2022 9:16 pm